Reata Pharmaceuticals Given New 105.00 Price Target at Stifel Nicolaus
RETADelisted Stock | USD 109.67 3.31 2.93% |
About 62% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Reata |
Reata Pharmaceuticals had its price objective increased by equities researchers at Stifel Nicolaus from 75.00 to 105.00 in a research note issued to investors on Wednesday, The Fly reports. Stifel Nicolaus target price indicates a potential upside of 20.95 percent from the companys previous close. Several other research analysts have also recently
Read at thelincolnianonline.com
Reata Pharmaceuticals Fundamental Analysis
We analyze Reata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Reata Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Reata Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reata Pharmaceuticals Related Equities
PTCT | PTC Therapeutics | 18.66 | ||||
VIR | Vir Biotechnology | 2.39 | ||||
CVAC | CureVac NV | 1.74 | ||||
AKRO | Akero Therapeutics | 0.28 | ||||
KRYS | Krystal Biotech | 1.27 | ||||
TERN | Terns Pharmaceuticals | 1.44 | ||||
VKTX | Viking Therapeutics | 2.70 | ||||
MDGL | Madrigal Pharmaceuticals | 2.94 | ||||
SRPT | Sarepta Therapeutics | 4.04 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |